1,000.08
1.06 (0.11%)
| Previous Close | 999.02 |
| Open | 1,003.31 |
| Volume | 6,744 |
| Avg. Volume (3M) | 536,717 |
| Market Cap | 110,243,823,616 |
| Price / Earnings (TTM) | 26.50 |
| Price / Earnings (Forward) | 20.66 |
| Price / Sales | 8.55 |
| Price / Book | 3.94 |
| 52 Weeks Range | |
| Earnings Date | 31 Oct 2024 |
| Profit Margin | 32.04% |
| Operating Margin (TTM) | 30.83% |
| Diluted EPS (TTM) | 37.80 |
| Quarterly Revenue Growth (YOY) | 12.30% |
| Quarterly Earnings Growth (YOY) | 47.90% |
| Total Debt/Equity (MRQ) | 9.58% |
| Current Ratio (MRQ) | 5.44 |
| Operating Cash Flow (TTM) | 4.07 B |
| Levered Free Cash Flow (TTM) | 2.09 B |
| Return on Assets (TTM) | 7.62% |
| Return on Equity (TTM) | 16.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Regeneron Pharmaceuticals, Inc. | Bearish | Bullish |
Stockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Value |
| % Held by Insiders | 1.53% |
| % Held by Institutions | 89.75% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 1,300.00 (Guggenheim, 29.99%) | Buy |
| 1,300.00 (BMO Capital, 29.99%) | Buy | |
| Median | 1,200.00 (19.99%) | |
| Low | 1,015.00 (Cantor Fitzgerald, 1.49%) | Hold |
| Average | 1,195.55 (19.55%) | |
| Total | 9 Buy, 2 Hold | |
| Avg. Price @ Call | 1,078.10 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 16 Oct 2024 | 1,137.00 (13.69%) | Buy | 1,007.96 |
| 24 Sep 2024 | 1,200.00 (19.99%) | Buy | 1,045.98 | |
| RBC Capital | 04 Oct 2024 | 1,260.00 (25.99%) | Buy | 1,012.82 |
| 24 Sep 2024 | 1,252.00 (25.19%) | Buy | 1,045.98 | |
| BMO Capital | 24 Sep 2024 | 1,300.00 (29.99%) | Buy | 1,045.98 |
| Leerink Partners | 24 Sep 2024 | 1,077.00 (7.69%) | Hold | 1,045.98 |
| Wells Fargo | 23 Sep 2024 | 1,200.00 (19.99%) | Buy | 1,091.98 |
| 02 Aug 2024 | 1,200.00 (19.99%) | Buy | 1,082.19 | |
| Cantor Fitzgerald | 16 Sep 2024 | 1,015.00 (1.49%) | Hold | 1,153.08 |
| 09 Sep 2024 | 1,015.00 (1.49%) | Hold | 1,144.77 | |
| Piper Sandler | 23 Aug 2024 | 1,242.00 (24.19%) | Buy | 1,199.12 |
| 19 Jul 2024 | 1,166.00 (16.59%) | Buy | 1,063.60 | |
| Barclays | 02 Aug 2024 | 1,220.00 (21.99%) | Buy | 1,082.19 |
| Guggenheim | 02 Aug 2024 | 1,300.00 (29.99%) | Buy | 1,082.19 |
| 18 Jul 2024 | 1,180.00 (17.99%) | Buy | 1,067.26 | |
| JP Morgan | 02 Aug 2024 | 1,200.00 (19.99%) | Buy | 1,082.19 |
| TD Cowen | 23 Jul 2024 | 1,200.00 (19.99%) | Buy | 1,055.57 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |